AbbVie and the Cystic Fibrosis Foundation have entered a strategic collaboration in which AbbVie will develop a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator compound licensed from the Foundation. Under the agreement, AbbVie will advance the potentiator into clinical development for potential use in combination treatments for cystic fibrosis (CF). Financial terms were not disclosed. “We believe the fastest way to deliver transformational medicines for patients i...